首页> 美国卫生研究院文献>BMJ Open >Study protocol for investigating the performance of an automated blood test measuring GFAP and UCH-L1 in a prospective observational cohort of patients with mild traumatic brain injury: European BRAINI study
【2h】

Study protocol for investigating the performance of an automated blood test measuring GFAP and UCH-L1 in a prospective observational cohort of patients with mild traumatic brain injury: European BRAINI study

机译:研究方案用于研究自动验血测量GFAP和UCH-L1在患有轻度创伤性脑损伤患者患者的预期血液测试的性能:欧洲脑卒中研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mild traumatic brain injury (mTBI) is a common cause of clinical consultation in the emergency department. Patients with mTBI may undergo brain CT scans based on clinical criteria. However, the proportion of patients with brain lesions on CT is very low. Two serum biomarkers, glial fibrillar acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), have been shown to discriminate patients regarding the presence or absence of brain lesions on initial CT scan when assessed within the first 12 hours after TBI. However, the current technique for measuring serum concentrations of GFAP and UCH-L1 is manual and time consuming, which may hinder its use in routine clinical practice. This study assesses the diagnostic accuracy of an automated assay for the measurement of serum GFAP and UCH-L1 in a cohort of patients with mTBI who received a CT scan as the standard of care.
机译:轻度创伤性脑损伤(MTBI)是急诊部门临床咨询的常见原因。 MTBI患者可以根据临床标准进行脑CT扫描。然而,CT上脑病变患者的比例非常低。已经证明了两种血清生物标志物,胶质纤维酸性蛋白(GFAP)和遍突素羧酸末端水解酶L1(UCH-L1),以区分患者在在前12小时内评估时初始CT扫描的存在或不存在脑病变TBI。然而,用于测量GFAP和UCH-L1的血清浓度的当前技术是手动和耗时的,这可能阻碍其在常规临床实践中的使用。该研究评估了在接受CT扫描的MTBI患者中测量血清GFAP和UCH-L1的自动测定的诊断准确性,作为护理标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号